ANGIOSARCOMA
Clinical trials for ANGIOSARCOMA explained in plain language.
Never miss a new study
Get alerted when new ANGIOSARCOMA trials appear
Sign up with your email to follow new studies for ANGIOSARCOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New vaccine trial targets rare skin cancer
⭐️ VACCINE ⭐️ TerminatedThis early-stage study was designed to test a personalized mRNA vaccine for people with a rare skin cancer called cutaneous angiosarcoma. The vaccine is made from the patient's own tumor and aims to teach the immune system to fight the cancer. The main goal was to find the highes…
Matched conditions: ANGIOSARCOMA
Phase: PHASE1 • Sponsor: M.D. Anderson Cancer Center • Aim: ⭐️ VACCINE ⭐️
Last updated May 26, 2026 02:47 UTC
-
Immunotherapy duo takes on rare tumors in nationwide trial
Disease control OngoingThis study tests two immunotherapy drugs, nivolumab and ipilimumab, in adults with over 50 types of rare cancers. The goal is to see if this drug combination can shrink tumors or stop them from growing. The trial is no longer enrolling new participants, but results will help guid…
Matched conditions: ANGIOSARCOMA
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 26, 2026 03:13 UTC
-
New hope for rare cancer: experimental combo targets angiosarcoma
Disease control OngoingThis study tests a new drug combination (VO and pembrolizumab) in 18 adults with advanced angiosarcoma, a rare cancer of the blood vessels. Participants must have already tried immunotherapy without success. The goal is to see if the treatment can shrink tumors and control the di…
Matched conditions: ANGIOSARCOMA
Phase: PHASE2 • Sponsor: Varun Monga, MBBS • Aim: Disease control
Last updated May 26, 2026 03:12 UTC
-
New hope for rare cancers: eribulin shows promise in early trial
Disease control OngoingThis study tested the drug eribulin in 13 people with two rare cancers of the blood vessels: angiosarcoma and epithelioid hemangioendothelioma (EHE). The goal was to see if the drug could shrink tumors or stop them from growing. Participants had advanced disease that had already …
Matched conditions: ANGIOSARCOMA
Phase: PHASE2 • Sponsor: Massachusetts General Hospital • Aim: Disease control
Last updated May 26, 2026 03:09 UTC
-
New drug duo aims to boost immune system against tough cancers
Disease control OngoingThis early-stage study tests two experimental drugs (botensilimab and balstilimab) that help the immune system fight cancer. It includes about 500 adults with advanced solid tumors like lung, ovarian, or colorectal cancer that haven't responded to standard treatments. The main go…
Matched conditions: ANGIOSARCOMA
Phase: PHASE1 • Sponsor: Agenus Inc. • Aim: Disease control
Last updated May 22, 2026 14:02 UTC